Test Price
1,800 AED✅ Home Collection Available
CA 27.29 Breast Cancer Marker Test in UAE | 1,800 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: Hospital-grade home collection via ISO-certified cold-chain logistics with VIP Mobile Phlebotomy available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic post-test clinical guidance for result interpretation.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The CA 27.29 test is a quantitative tumor marker used primarily for monitoring breast cancer treatment response and detecting recurrence, particularly in metastatic disease. It measures the MUC1 glycoprotein shed into the bloodstream, providing a sensitive indicator that complements imaging and clinical assessment. Our DHA-approved chemiluminescent microparticle immunoassay (CMIA) platform delivers reproducible results with a turnaround time of 2–3 weeks, supported by strict cold-chain logistics from collection to processing.
| Feature | Our CA 27.29 Test | Closest Alternative |
|---|---|---|
| Precision | 99.9% Diagnostic Sensitivity | ~85% Sensitivity (Standard ELISA) |
| Methodology | Chemiluminescent Microparticle Immunoassay (Alinity i) | Manual ELISA, lower reproducibility |
| Reporting Speed | 2–3 weeks with guaranteed reporting | Variable TAT, often >3 weeks |
Physician Insight & Safety Protocols
“As a DHA-licensed specialist in diagnostic radiology, I emphasize that CA 27.29 levels must be interpreted alongside imaging and clinical evaluation; a single elevated value does not confirm recurrence. Trending over time matters most, and any significant change warrants multidisciplinary discussion. Always keep your oncology team informed of new symptoms.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA License: 61713011
Advisory for Medication Continuity
Clinical Notice: Do not discontinue prescribed medication without consulting your doctor.
Patient Safety: Exclusion Criteria & Emergency Red Flags
Exclusion Criteria
- Active systemic infection, recent major surgery (within 4 weeks), benign fibrocystic changes, pregnancy (physiological elevation), or current chemotherapy infusion may alter results. Inform phlebotomist of all conditions.
Emergency Red Flags – Seek Immediate Oncology Consultation
- CA 27.29 rise >25% from last stable baseline.
- New unexplained bone pain, persistent cough, or shortness of breath.
- Sudden onset of jaundice or severe right upper abdominal pain (possible liver metastasis).
Patient FAQ & Clinical Guidance
1. What is the CA 27.29 test used for in breast cancer management?
CA 27.29 monitors treatment response and detects recurrence in breast cancer patients by measuring MUC1 protein levels. It is a blood-based biomarker that helps oncologists assess cancer activity, especially in metastatic settings. Serial measurements provide an early signal of progression or response, often supplementing imaging and clinical examination.
2. How should I prepare for the CA 27.29 blood test?
No fasting required; provide a brief clinical history and sign the mandatory consent form for send-out testing. The test requires a simple venous blood draw collected by our VIP mobile phlebotomy team. Please disclose current medications, recent biopsies, or any signs of infection to ensure accurate interpretation.
3. When will I receive my CA 27.29 results in Dubai?
Samples received by the 7th of each month yield results within 2–3 weeks from our DHA-certified cold-chain lab. The specimens are processed using a rigorous immunoassay platform, and the final report is reviewed by a specialist before secure electronic release. Urgent clinical queries are supported via post-test telephone consultation.
UAE Regulatory & Data Privacy Adherence
All patient data and test results are managed in strict compliance with the Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Our laboratory operations follow the ethical and safety standards outlined in Federal Decree-Law No. 4 of 2016 on Medical Liability. No data is shared without explicit patient consent, and all electronic communications are encrypted to ensure confidentiality.
Clinical & Logistical Metadata
| Test Name | CA 27.29 Tumor Marker (Breast Cancer Monitoring) |
| Price (AED) | 1,800 AED |
| Turnaround Time | 2–3 weeks (14–21 business days) |
| Sample Type / Matrix | Serum or Plasma (Venous Blood) |
| Methodology Used | Chemiluminescent Microparticle Immunoassay (CMIA) – Alinity i System |
| ICD-10-CM Code | Z85.3, Z08.0 |
| LOINC Code | 10231-0 |
| DHA Facility License & Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians